Vertex Reports Second-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex (VRTX) PT Raised to $203 at RBC Capital
July 26, 2018 8:44 AM EDTRBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $203.00 (from $202.00) while maintaining an Outperform rating.
Analyst Brian Abrahams commented, "Despite rising expectations into 2Q, an impressive beat for VRTX's CF franchise."
... MoreVertex (VRTX) PT Raised to $204 at BMO Capital; 'Stellar Revenue'
July 26, 2018 7:11 AM EDTBMO Capital raised its price target on Vertex (NASDAQ: VRTX) to $204.00 (from $191.00) while maintaining an Outperform rating following results.
Analyst Do Kim commented, "We raise our revenue estimates and target price to $204 from $191, following stellar 2Q18 CF revenues that easily exceeded our and... More
Vertex (VRTX) PT Raised to $200 at Oppenheimer
July 26, 2018 6:59 AM EDTOppenheimer raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $180.00) while maintaining an Outperform rating following results.
Analyst Hartaj Singh commented, "Vertex (VRTX) reported 2Q18 sales/earnings and provided a business update to investors on 7/25. Based on the company's robust results and... More
Vertex Pharma (VRTX) Tops Q2 EPS by 19c; Raises Outlook
July 25, 2018 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.94, $0.19 better than the analyst estimate of $0.75. Revenue for the quarter came in at $750 million versus the consensus estimate of $680.98 million.
Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion; reiterates full-year 2018... More
